Immunic publishes investor presentation on oral immunology pipeline led by vidofludimus calcium in multiple sclerosis

IMMUNIC INC

IMUX

0.00

Immunic highlighted late-stage focus on oral immunology drugs led by vidofludimus calcium (IMU-838) for multiple sclerosis.
Top-line data from Phase 3 ENSURE-1 and ENSURE-2 relapsing MS trials expected by end of 2026; an NDA targeted for mid-2027.
Subject to regulatory approval, commercial launch targeted for 2028; peak sales potential estimated at USD 3-7 billion across RMS and PMS.
Cash balance of USD 186.6 million as of March 31, 2026.
Strategic alternatives under review to advance IMU-856 in celiac disease; Phase 3 program initiation in PPMS expected later in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.